EPHB2
Summary: This gene encodes a member of the Eph receptor family of receptor tyrosine kinase transmembrane glycoproteins. These receptors are composed of an N-terminal glycosylated ligand-binding domain, a transmembrane region and an intracellular kinase domain. They bind ligands called ephrins and are involved in diverse cellular processes including motility, division, and differentiation. A distinguishing characteristic of Eph-ephrin signaling is that both receptors and ligands are competent to transduce a signaling cascade, resulting in bidirectional signaling. This protein belongs to a subgroup of the Eph receptors called EphB. Proteins of this subgroup are distinguished from other members of the family by sequence homology and preferential binding affinity for membrane-bound ephrin-B ligands. Allelic variants are associated with prostate and brain cancer susceptibility. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2015].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| EPH receptor B2 | MIM:600997 | Ensembl:ENSG00000133216 | HGNC:HGNC:3393 | PA27825 | 1p36.12 |
GO terms in EPHB2
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | ISS | GO:0001540 | amyloid-beta binding |
| MF | IBA | GO:0004709 | MAP kinase kinase kinase activity |
| MF | EXP | GO:0004713 | protein tyrosine kinase activity |
| MF | IBA | GO:0004713 | protein tyrosine kinase activity |
| MF | ISS | GO:0004713 | protein tyrosine kinase activity |
| MF | IBA | GO:0004714 | transmembrane receptor protein tyrosine kinase activity |
| MF | IBA | GO:0004888 | transmembrane signaling receptor activity |
| MF | IBA | GO:0005005 | transmembrane-ephrin receptor activity |
| MF | ISS | GO:0005005 | transmembrane-ephrin receptor activity |
| MF | TAS | GO:0005005 | transmembrane-ephrin receptor activity |
| MF | IEA | GO:0005102 | signaling receptor binding |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0005524 | ATP binding |
| MF | IEA | GO:0008046 | axon guidance receptor activity |
| MF | IBA | GO:0031434 | mitogen-activated protein kinase kinase binding |
| MF | IEA | GO:0042802 | identical protein binding |
| MF | ISS | GO:0044877 | protein-containing complex binding |
| BP | ISS | GO:0001525 | angiogenesis |
| BP | ISS | GO:0001655 | urogenital system development |
| BP | ISS | GO:0001933 | negative regulation of protein phosphorylation |
| BP | IBA | GO:0007275 | multicellular organism development |
| BP | TAS | GO:0007399 | nervous system development |
| BP | ISS | GO:0007411 | axon guidance |
| BP | ISS | GO:0007413 | axonal fasciculation |
| BP | ISS | GO:0007611 | learning or memory |
| BP | ISS | GO:0007612 | learning |
| BP | IBA | GO:0009968 | negative regulation of signal transduction |
| BP | ISS | GO:0010628 | positive regulation of gene expression |
| BP | ISS | GO:0016310 | phosphorylation |
| BP | ISS | GO:0018108 | peptidyl-tyrosine phosphorylation |
| BP | IEA | GO:0021631 | optic nerve morphogenesis |
| BP | IEA | GO:0021952 | central nervous system projection neuron axonogenesis |
| BP | ISS | GO:0022038 | corpus callosum development |
| BP | IBA | GO:0030154 | cell differentiation |
| BP | IEA | GO:0031290 | retinal ganglion cell axon guidance |
| BP | ISS | GO:0031915 | positive regulation of synaptic plasticity |
| BP | IBA | GO:0033674 | positive regulation of kinase activity |
| BP | ISS | GO:0042472 | inner ear morphogenesis |
| BP | IBA | GO:0043066 | negative regulation of apoptotic process |
| BP | IBA | GO:0043410 | positive regulation of MAPK cascade |
| BP | ISS | GO:0046580 | negative regulation of Ras protein signal transduction |
| BP | ISS | GO:0048013 | ephrin receptor signaling pathway |
| BP | TAS | GO:0048013 | ephrin receptor signaling pathway |
| BP | ISS | GO:0048168 | regulation of neuronal synaptic plasticity |
| BP | IEA | GO:0048170 | positive regulation of long-term neuronal synaptic plasticity |
| BP | IEA | GO:0048593 | camera-type eye morphogenesis |
| BP | IEA | GO:0050771 | negative regulation of axonogenesis |
| BP | ISS | GO:0050878 | regulation of body fluid levels |
| BP | ISS | GO:0051389 | inactivation of MAPKK activity |
| BP | ISS | GO:0051965 | positive regulation of synapse assembly |
| BP | ISS | GO:0060021 | roof of mouth development |
| BP | ISS | GO:0060996 | dendritic spine development |
| BP | ISS | GO:0060997 | dendritic spine morphogenesis |
| BP | ISS | GO:0070373 | negative regulation of ERK1 and ERK2 cascade |
| BP | IBA | GO:0070374 | positive regulation of ERK1 and ERK2 cascade |
| BP | ISS | GO:0071679 | commissural neuron axon guidance |
| BP | IBA | GO:0099557 | trans-synaptic signaling by trans-synaptic complex, modulating synaptic transmission |
| BP | IEA | GO:0099557 | trans-synaptic signaling by trans-synaptic complex, modulating synaptic transmission |
| BP | IEA | GO:0106028 | neuron projection retraction |
| BP | IBA | GO:1900273 | positive regulation of long-term synaptic potentiation |
| BP | ISS | GO:1900273 | positive regulation of long-term synaptic potentiation |
| BP | ISS | GO:1903078 | positive regulation of protein localization to plasma membrane |
| BP | ISS | GO:1904782 | negative regulation of NMDA glutamate receptor activity |
| BP | ISS | GO:1904783 | positive regulation of NMDA glutamate receptor activity |
| CC | TAS | GO:0005576 | extracellular region |
| CC | IDA | GO:0005634 | nucleus |
| CC | IBA | GO:0005737 | cytoplasm |
| CC | TAS | GO:0005829 | cytosol |
| CC | IDA | GO:0005886 | plasma membrane |
| CC | TAS | GO:0005886 | plasma membrane |
| CC | IBA | GO:0005887 | integral component of plasma membrane |
| CC | ISS | GO:0005887 | integral component of plasma membrane |
| CC | ISS | GO:0030424 | axon |
| CC | ISS | GO:0030425 | dendrite |
| CC | IBA | GO:0043005 | neuron projection |
| CC | IEA | GO:0043025 | neuronal cell body |
| CC | IBA | GO:0043235 | receptor complex |
| CC | TAS | GO:0098794 | postsynapse |
Gene expression in normal tissue: EPHB2
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in EPHB2
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-1266738 | Developmental Biology |
| reactome | R-HSA-1266738 | Developmental Biology |
| reactome | R-HSA-2682334 | EPH-Ephrin signaling |
| reactome | R-HSA-2682334 | EPH-Ephrin signaling |
| reactome | R-HSA-373760 | L1CAM interactions |
| reactome | R-HSA-3928662 | EPHB-mediated forward signaling |
| reactome | R-HSA-3928662 | EPHB-mediated forward signaling |
| reactome | R-HSA-3928664 | Ephrin signaling |
| reactome | R-HSA-3928664 | Ephrin signaling |
| reactome | R-HSA-3928665 | EPH-ephrin mediated repulsion of cells |
| reactome | R-HSA-422475 | Axon guidance |
| reactome | R-HSA-422475 | Axon guidance |
| pid | ephbfwdpathway | EPHB forward signaling |
| pid | ephrinbrevpathway | Ephrin B reverse signaling |
| pid | syndecan_2_pathway | Syndecan-2-mediated signaling events |
| kegg | hsa04360 | Axon guidance - Homo sapiens (human) |
| netpath | Pathway_Alpha6Beta4Integrin | Alpha6Beta4Integrin |
| netpath | Pathway_EGFR1 | EGFR1 |
| wikipathways | WP2038 | Regulation of Microtubule Cytoskeleton |
| wikipathways | WP288 | NLR Proteins |
| wikipathways | WP3 | Transcriptional activation by NRF2 |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD506 | Fedratinib | 3 |
| iGMDRD562 | Navitoclax | 3 |
| iGMDRD286 | Nsc 632839 | 3 |
| iGMDRD874 | BRD8958 | 1 |
| iGMDRD268 | Cerulenin | 2 |
| iGMDRD300 | Tozasertib | 3 |
| iGMDRD158 | NSC141540 | 3 |
| iGMDRD137 | Indisulam | 3 |
| iGMDRD318 | PAC-1 | 6 |
| iGMDRD105 | Triptolide | 3 |
| iGMDRD782 | DC-45-A2 | 3 |
| iGMDRD152 | 179324-69-7 | 4 |
| iGMDRD634 | SCHEMBL2608041 | 3 |
| iGMDRD154 | NSC23766 | 3 |
| iGMDRD394 | BX-795 | 3 |
| iGMDRD512 | nutlin 3 | 3 |
| iGMDRD126 | Tipifarnib | 7 |
| iGMDRD84 | Lovastatin acid | 3 |
| iGMDRD781 | Sirolimus | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in EPHB2
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.